

Resource Summary Report

Generated by [RRID](#) on Aug 3, 2026

HLA Class 1 ABC antibody [EMR8-5]

RRID:AB_1269092

Type: Antibody

Proper Citation

Abcam Cat# ab70328, RRID:AB_1269092

Antibody Information

URL: http://antibodyregistry.org/AB_1269092

Proper Citation: Abcam Cat# ab70328, RRID:AB_1269092

Target Antigen: HLA Class 1 ABC antibody [EMR8-5]

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Western Blot; Immunohistochemistry - fixed; Immunohistochemistry; Flow Cytometry; Flow Cyt, IHC-P, WB

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: HLA Class 1 ABC antibody [EMR8-5]

Description: This monoclonal targets HLA Class 1 ABC antibody [EMR8-5]

Target Organism: human

Antibody ID: AB_1269092

Vendor: Abcam

Catalog Number: ab70328

Record Creation Time: 20250819T222427+0000

Record Last Update: 20250820T020532+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for HLA Class 1 ABC antibody [EMR8-5].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Huber MK, et al. (2025) Beta cell dysfunction occurs independently of insulinitis in type 1 diabetes pathogenesis. Cell reports, 44(9), 116174.

Chiu PH, et al. (2025) Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy. Cell reports. Medicine, 6(11), 102448.

Huyghe N, et al. (2025) Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan. Cell reports. Medicine, 6(7), 102201.

Oka T, et al. (2025) Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer. Cell reports, 44(5), 115561.

Hirano S, et al. (2025) Dual molecular therapy targeting tumor cell heterogeneity improves therapeutic efficacy in glioblastoma. iScience, 28(9), 113456.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Cell reports. Medicine, 5(2), 101397.

Patra M, et al. (2024) Senescence of human pancreatic beta cells enhances functional maturation through chromatin reorganization and promotes interferon responsiveness. Nucleic acids research, 52(11), 6298.

Liao TT, et al. (2024) Hypoxia-Induced Long Noncoding RNA HIF1A-AS2 Regulates Stability of MHC Class I Protein in Head and Neck Cancer. Cancer immunology research, 12(10), 1468.

Lin CJ, et al. (2024) Genetic interactions reveal distinct biological and therapeutic implications in breast cancer. Cancer cell, 42(4), 701.

Samer C, et al. (2024) Multi-targeted loss of the antigen presentation molecule MR1 during HSV-1 and HSV-2 infection. *iScience*, 27(2), 108801.

Wang Z, et al. (2023) Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment. *Cell metabolism*, 35(7), 1209.

Cruz SM, et al. (2023) Intratumoral NKp46+ natural killer cells are spatially distanced from T and MHC-I+ cells with prognostic implications in soft tissue sarcoma. *Frontiers in immunology*, 14, 1230534.

Kishton RJ, et al. (2022) Cancer genes disfavoring T cell immunity identified via integrated systems approach. *Cell reports*, 40(5), 111153.

Zhang Z, et al. (2022) A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. *Cancer cell*, 40(9), 1060.

Xiong X, et al. (2022) Emerging enterococcus pore-forming toxins with MHC/HLA-I as receptors. *Cell*, 185(7), 1157.

Ferrian S, et al. (2021) Multiplexed imaging reveals an IFN- γ -driven inflammatory state in nivolumab-associated gastritis. *Cell reports. Medicine*, 2(10), 100419.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.

McSharry BP, et al. (2020) Virus-Mediated Suppression of the Antigen Presentation Molecule MR1. *Cell reports*, 30(9), 2948.

Kanie K, et al. (2019) Pathogenesis of Anti-PIT-1 Antibody Syndrome: PIT-1 Presentation by HLA Class I on Anterior Pituitary Cells. *Journal of the Endocrine Society*, 3(11), 1969.

Wei J, et al. (2019) Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance. *Molecular cell*, 73(6), 1162.